NEJM: Semaglutide and Cardiovascular Outcomes in Patients With Obesity Without Diabetes
TAKE-HOME MESSAGE In this international placebo-controlled trial involving 17,604 patients with established cardiovascular disease and a BMI of 27 kg/m2 or greater but without diabetes, once-weekly